Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

The phase III KEYNOTE-689 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment for patients newly diagnosed with stage 3 or 4A, resected, locally advanced head and neck squamous cell carcinoma met its primary endpoint of event-free survival.

October 11, 2024

Vol.50 No.38

Regulatory News

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

Scientists at the University of Oxford are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 (approximately US$800,000) for the study over the next three years to support lab research into the vaccine.

October 04, 2024

Vol.50 No.37

Regulatory News

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.

September 27, 2024

Vol.50 No.36

Drugs & Targets

EU CHMP gives positive opinion to Keytruda for two types of gynecologic cancers

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted positive opinions recommending approval of Keytruda (pembrolizumab), an anti-PD-1 therapy, for two indications in gynecologic cancers.

September 27, 2024

Vol.50 No.36

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

YOU MAY BE INTERESTED IN

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

EU CHMP gives positive opinion to Keytruda for two types of gynecologic cancers

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

YOU MAY BE INTERESTED IN

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitorsVote may lead to rollback of some indications held by BMS and Merck

Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitorsVote applies across drugs and indications

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

EU CHMP gives positive opinion to Keytruda for two types of gynecologic cancers

Can you spare 10 minutes to complete a survey?

Login

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications